Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Nes-Ziona, Israel, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced today that the European and Int'l Shock...
-
Nes-Ziona, Israel, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the European Patent Office granted a new patent (#EP 2...
-
Nes-Ziona, Israel, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the European Molecular Biology...
-
Nes-Ziona, Israel, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced the first presentation of its preclinical...
-
Nes-Ziona, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israeli Patent Authority issued a notice of...
-
Nes-Ziona, Israel, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate...
-
Nes Ziona, Israel, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the safety review committee of the...
-
The Company's shares, which currently trade on NASDAQ, will be dual-listed on the Tel Aviv Stock Exchange (TASE) starting on July 22, 2019, under the symbol ENLV Tel-Aviv, Israel, July 16, 2019 ...
-
Nes-Ziona, Israel, June 18, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Australian Patent Office (IP Australia) granted a...
-
Nes Ziona, Israel, June 06, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today provided a clinical update on the positive safety...